We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





GK Pharmaceuticals Accu-Right SARS-CoV-2 RT-PCR Kit Granted FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 23 Sep 2020
GK Pharmaceuticals CMO (Manatí, Puerto Rico, USA) has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the company’s GK ACCU-RIGHT SARS-CoV-2 assay.

The GK ACCU-RIGHT SARS-CoV-2 assay is an in vitro diagnostic RT-PCR test intended for the qualitative detection of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in upper respiratory specimens (such as nasopharyngeal, oropharyngeal, midturbinate, and nasal swabs) collected from individuals suspected of COVID-19 by their healthcare provider. More...
The assay utilizes primers and probes targeting RNA from the virus nucleocapsid phosphoprotein (N) gene of the SARS-CoV-2 coronavirus. Testing consists of nucleic acid extraction followed by RT-PCR.

The GK ACCU-RIGHT SARS-CoV-2 RT-PCR KIT utilizes primers and probes targeting RNA from the SARS-CoV-2 coronavirus N gene. The panel is designed for specific detection of two unique regions (N1 and N2) of the SARS-CoV-2 (two primer/probe sets). The primer and probe sets are based on the US Centers for Disease Control and Prevention (US CDC) 2019-nCoV Real-Time RT-PCR Diagnostic Panel. An additional primer/probe set to detect the human RNase P gene (RP) in control samples and clinical specimens is also included in the panel. The internal control RP will serve as an endogenous nucleic acid extraction control present in all properly collected patient simples and serves as both an extraction control and an internal amplification control. All three targets are amplified in individual reactions.

RNA isolated from upper respiratory specimens is reverse transcribed to cDNA and subsequently amplified using Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument with SDS software version 1.4. During the amplification process, the probe anneals to a specific target sequence located between the forward and reverse primers. During the extension phase of the PCR cycle, the 5’ nuclease activity of Taq polymerase degrades the bound probe, causing the reporter dye (FAM) to separate from the quencher dye (BHQ), generating a fluorescent signal. Fluorescence intensity is monitored at each PCR cycle by Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument.

Related Links:
GK Pharmaceuticals CMO


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.